India Dr Reddy's sees 10 pct revenue growth in FY10

BANGALORE May 18 (Reuters) - Indian drug maker Dr Reddy's Laboratories Ltd (REDY.BO) expects revenue growth of 10 percent in the fiscal year to March 2010 because of new product launches, its chief executive officer said on Monday. Germany's Betapharm, which Dr Reddy's bought in 2006 for $572 million, was seeing volume growth but the pressure on pricing remained, G.V. Prasad told Reuters after the company reported its March quarter earnings. (Reporting by Sumeet Chatterjee; Editing by John Mair)